Close Menu

NEW YORK (GenomeWeb) – Proteomics firm Caprion this week launched its CNS ProteoCarta panel for the study of central nervous system diseases.

A multiple-reaction monitoring mass spec-based assay that measures the levels of 142 proteins linked to neurological disorders including Alzheimer's and Parkinson's disease, the panel is the first of several such products aimed at specific disease areas that Caprion plans to launch in the coming year, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
17
Sponsored by
ACD

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.